公开(公告)号：US12209144B2

公开(公告)日：2025-01-28

申请号：US17296679

申请日：2019-11-26

Applicant: Novartis AG

Inventor： Alec Nathanson Flyer ,  Andrei Alexandrovich Golosov ,  Philipp Grosche ,  Ian Lewis ,  Eugene Yuejin Liu ,  Andreas Marzinzik ,  Lauren Gilchrist Monovich ,  Johannes Ottl ,  Tajesh Jayprakash Patel ,  Patrick Crawford Reid ,  Mohindra Seepersaud

IPC: C07K7/64 ,  A61K38/12 ,  A61K45/06 ,  A61K38/00

Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are described herein.

公开(公告)号：US11813306B2

公开(公告)日：2023-11-14

申请号：US17200471

申请日：2021-03-12

Applicant: NOVARTIS AG

Inventor： Karin Briner ,  Brian Addison Dechristopher ,  Alec Nathanson Flyer ,  Andrei Alexandrovich Golosov ,  Philipp Grosche ,  Eugene Yuejin Liu ,  Justin Yik Ching Mao ,  Lauren Gilchrist Monovich ,  Tajesh Jayprakash Patel ,  Liansheng Su ,  Lihua Yang ,  Rui Zheng

IPC: A61K38/12 ,  A61K45/06 ,  C07K5/12

CPC classification number: A61K38/12 ,  A61K45/06 ,  C07K5/126

Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I):




or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.

公开(公告)号：US11026993B2

公开(公告)日：2021-06-08

申请号：US16695843

申请日：2019-11-26

Applicant: NOVARTIS AG

Inventor： Karin Briner ,  Brian Addison Dechristopher ,  Alec Nathanson Flyer ,  Andrei Alexandrovich Golosov ,  Philipp Grosche ,  Eugene Yuejin Liu ,  Justin Yik Ching Mao ,  Lauren Gilchrist Monovich ,  Tajesh Jayprakash Patel ,  Carina Cristina Sanchez ,  Liansheng Su ,  Lihua Yang ,  Rui Zheng

IPC: A61K38/00 ,  A61K38/12 ,  A61K45/06 ,  C07K5/12

Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.